Zhengye Biotechnology Holding Limited (ZYBT) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Zhengye Biotechnology Holding Limited (ZYBT) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, with a market capitalization near $41.2M, listed on NASDAQ, employing roughly 278 people, carrying a beta of -2.45 to the broader market. Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. Led by Songlin Song, public since 2025-01-07.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for ZYBT as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →